SOLIFENACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H26N2O2
Molecular Weight	362.4647
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(O[C@H]1CN2CCC1CC2)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5

InChI

InChIKey=FBOUYBDGKBSUES-VXKWHMMOSA-N

InChI=1S/C23H26N2O2/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19/h1-9,18,21-22H,10-16H2/t21-,22-/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/vesicare-drug.htm https://www.drugs.com/mtm/solifenacin.html http://www.wikidoc.org/index.php/Solifenacin

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine. It is FDA approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Common adverse reactions include constipation, Xerostomia. Inhibitors of CYP3A4 may increase the concentration of Solifenacin. Vice versa, CYP3A4 Inducers decrease concentration.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M3 159 Target ID: CHEMBL245 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15190387 \| https://www.ncbi.nlm.nih.gov/pubmed/16465186 \| https://www.ncbi.nlm.nih.gov/pubmed/19446545 \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2778	10.0 nM [Ki]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/16465186 \| https://www.ncbi.nlm.nih.gov/pubmed/19446545 \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2778	125.0 nM [Ki]
Muscarinic acetylcholine receptor M1 169 Target ID: CHEMBL216 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/16465186 \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2778	25.0 nM [Ki]
Muscarinic acetylcholine receptor M4 86 Target ID: CHEMBL1821 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2778	7.73 null [pKi]
Muscarinic acetylcholine receptor M5 62 Target ID: CHEMBL2035 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/19029429 \| http://www.drugbank.ca/drugs/DB01591	Antagonist 2778	7.46 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency 4 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021518s016lbl.pdf	Primary		Approved 8429	VESICARE Approved Use VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency (1) Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
14.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
820 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
50.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15206986	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		SOLIFENACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf			SOLIFENACIN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/15317830 Page: p.1028	healthy, 19-40 n = 6 Health Status: healthy Age Group: 19-40 Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/15317830 Page: p.1028	Sources: https://pubmed.ncbi.nlm.nih.gov/15317830 Page: p.1028
30 mg 1 times / day multiple, oral Highest studied dose Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15317830 Page: p.1029	healthy, 20-35 n = 8 Health Status: healthy Age Group: 20-35 Sex: M Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/15317830 Page: p.1029	Sources: https://pubmed.ncbi.nlm.nih.gov/15317830 Page: p.1029
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.4	unhealthy n = 1233 Health Status: unhealthy Condition: Overactive bladder Population Size: 1233 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.4	Disc. AE: Dry mouth... AEs leading to discontinuation/dose reduction: Dry mouth (1.5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.4
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Overactive bladder Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.1	Disc. AE: Angioedema, Anaphylactic reaction... AEs leading to discontinuation/dose reduction: Angioedema Anaphylactic reaction (rare) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Dry mouth	1.5% Disc. AE	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.4	unhealthy n = 1233 Health Status: unhealthy Condition: Overactive bladder Population Size: 1233 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.4
Angioedema	Disc. AE	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Overactive bladder Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.1
Anaphylactic reaction	rare Disc. AE	10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Overactive bladder Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021518s012lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A 72 CYP2C19 1478	CYP2C19 991 CYP3A5 395 CYP2C8 693 CYP1A1 349 P-gp 1537

Drug as perpetrator

Target	Modality	Activity
CYP1A 121	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	not significant
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	not significant
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	not significant
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	not significant
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=51 Page: 51.0	yes [Inhibition 1.04 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=22 Page: 22,52	major	yes (co-administration study) Comment: Label: coadministration with ketoconazole increased the mean Cmax and AUC of solifenacin by 1.5 and 2.7 fold, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=22 Page: 22,52
CYP1A1 349	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=27 Page: 27.0	minor
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=22 Page: 22,27	minor
CYP2C8 693	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=27 Page: 27.0	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=27 Page: 27.0	minor
CYP3A5 395	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_biopharmr.pdf#page=27 Page: 27.0	minor
P-gp 1537	substrate 3367 Sources: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2125.2011.03961.x	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VESIcare_pharmr.pdf#page=35 Page: 35.0

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY543715	https://www.001chemical.com/chem/242478-37-1
AA Blocks	AA019FPZ	https://www.aablocks.com/goods/Goods/detail?id=AA019FPZ
AK Scientific, Inc. (AKSCI)	X4689	http://www.aksci.com/item_detail.php?cat=X4689
Aaron Chemicals	AR019GHR	http://www.aaronchem.com/242478-37-1
Acadechem	ACDX-012562	http://acadechemical.com/product/87283
Achemo Scientific Limited	AC-63428	http://www.achemo.com/search/?Keyword= 242478-37-1
Achemtek	0102-022129	http://www.achemtek.com/242478-37-1
Acorn PharmaTech	ACN-037989	http://www.acornpharmatech.com/
Adooq BioScience	A16947	https://www.adooq.com/solifenacin.html
Alfa Chemistry	242478-37-1	https://www.alfa-chemistry.com/cas_242478-37-1.htm
Alfa Chemistry	ACM180272144	https://www.alfa-chemistry.com/solifenacin-cas-180272-14-4-item-285040.htm
Alichem	189007421	http://www.alichem.com/en/products/180272-14-4.html
Ambinter	Amb20241303	http://www.ambinter.com/reference/20241303
Aurora Fine Chemicals LLC	K16.645.638	http://online.aurorafinechemicals.com/info?ID=K16.645.638
AvaChem Scientific	2557B	http://www.avachem.com/productSearch.asp?2557B
BLD Pharm	BD764111	http://www.bldpharm.com/products/180272-14-4.html
BLD Pharm	BD151698	http://www.bldpharm.com/products/242478-37-1.html
CSNpharm	CSN21835	https://www.csnpharm.com/products/solifenacin.html
Capot Chemical	23264	http://www.capotchem.com/en/23264.htm
Capot Chemical	PubChem23264	http://www.capotchem.com/en/23264.htm
Chem Scene	CS-8096	http://www.chemscene.com/242478-37-1.html
ChemMol	49419563	http://www.chemmol.com/chemmol/49419563.html
Chemenu	CM126714	http://www.chemenu.com/products/CM126714
Chemspace	CSSB00138412639	https://chem-space.com/CSSB00138412639
Chemspace	CSSS00020667699	https://chem-space.com/CSSS00020667699
Chemspace	CSSS00102523311	https://chem-space.com/CSSS00102523311
Chemspace	CSSS00116206880	https://chem-space.com/CSSS00116206880
DC Chemicals	DC9214	http://www.dcchemicals.com/product_show-Solifenacin.html
Debye Scientific	DB-001095	http://www.debyesci.com/DB-001095.html
Excenen	EX-A4180	https://www.excenen.com/searchresultlist.php?id=EX-A4180
Finetech	FT-0698075	http://www.finetechnology-ind.com/prod/detail/pub/242478-37-1.html
Finetech	FT-0778252	https://www.finetechnology-ind.com/prod/detail/pub/180272-14-4.html
Hairui	HR112258	http://www.hairuichem.com/en/product/242478-37-1.html
Lab Network	LN01345685	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01345685
MedChem Express	HY-A0034	https://www.medchemexpress.com/Solifenacin.html
MolPort	MolPort-023-220-809	https://www.molport.com/shop/molecule-link/MolPort-023-220-809
MolPort	MolPort-046-871-055	https://www.molport.com/shop/molecule-link/MolPort-046-871-055
Molcore	MC543715	https://www.molcore.com/product/242478-37-1
MuseChem	I012990	https://www.musechem.com/product/I012990.html
OChem	25997	http://www.ocheminc.com/index.php?act=psearch&pid=478S382
Smolecule	S006668	http://www.smolecule.com/products/s006668
Smolecule	S598639	https://www.smolecule.com/products/s598639
Smolecule	S635527	https://www.smolecule.com/products/s635527
Specs	AR-270/43507775	http://www.specs.net/enter.php?specsid=AR-270/43507775
Synblock Inc	SB17427	http://www.synblock.com/product/242478-37-1.html
THE BioTek	bt-255435	https://www.thebiotek.com/product/inhibitors/bt-255435
THE BioTek	bt-339594	https://www.thebiotek.com/product/others/bt-339594
Vitas-M Laboratory	STL484275	http://www.request.vitasmlab.com/index.php?option=com_search_stk&Itemid=22&stk=STL484275&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
Yuhao Chemical	YH48847	http://www.chemyuhao.com/242478-37-1.html
eNovation Chemicals	D591419	https://www.enovationchem.com/ProductDetails.asp?ProductID=D591419
eNovation Chemicals	D775303	https://www.enovationchem.com/ProductDetails.asp?ProductID=D775303
eNovation Chemicals	D962251	https://www.enovationchem.com/ProductDetails.asp?ProductID=D962251
iChemical	EBD2197604	http://www.ichemical.com/products/242478-37-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Gateways to clinical trials.	2004 Dec	15672123
Drug forecast--solifenacin: an investigational anticholinergic for overactive bladder.	2004 May	16553482
Gateways to clinical trials.	2004 Nov	15632957
Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder.	2004 Nov	15540755
Elevating our therapeutic expectations in overactive bladder.	2004 Oct	15543927
[Urinary incontinence: new pharmacologic therapies].	2004 Oct-Dec	15812946
Solifenacin in overactive bladder: a viewpoint by Hashim Hashim.	2005	16363889
Solifenacin in overactive bladder syndrome: a viewpoint by Scott Serels.	2005	16363888
Solifenacin in overactive bladder syndrome.	2005	16363887
Overactive bladder in the elderly: a guide to pharmacological management.	2005	16363885
Improving the tolerability of anticholinergic agents in the treatment of overactive bladder.	2005	15963006
Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg.	2005 Jan	15881477
New molecular entity: Vesicare, Yamanouchi/GlaxoSmithKline solifenacin.	2005 Jan	15700943
Improved quality of life in patients with overactive bladder symptoms treated with solifenacin.	2005 Jan	15638900
[Medical therapy of urinary incontinence].	2005 Jan	15609033
Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.	2005 Mar	15716204
Solifenacin and darifenacin for overactive bladder.	2005 Mar 14	15767976
Effect of age on the pharmacokinetics of solifenacin in men and women.	2005 May	15906588
[Drug discovery in the fields of urology: tamsulosin and solifenacin].	2005 Nov	16394579
The Q-T interval and antimuscarinic drugs.	2005 Nov	16238912
Solifenacin versus tolterodine--a head-to-head study: finally! But not final?	2005 Nov	16238911
Solifenacin in the management of the overactive bladder syndrome.	2005 Oct	16178992
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.	2005 Oct 20	16220976
Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.	2005 Sep	16291413
Role of muscarinic receptor antagonists in urgency and nocturia.	2005 Sep	16083453
Solifenacin in overactive bladder syndrome.	2006	16451092
The causes and consequences of overactive bladder.	2006 Apr	16620184
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment.	2006 Aug	16908335
Solifenacin significantly improves all symptoms of overactive bladder syndrome.	2006 Aug	16893438
New developments in the treatment of urinary incontinence.	2006 Dec	17268395
Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment.	2006 Dec	17170513
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.	2006 Dec	17125433
Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.	2006 Dec	17109616
Newer agents for the management of overactive bladder.	2006 Dec 15	17186712
Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.	2006 Jan	16393429
Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.	2006 Jan	16310930
[Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].	2006 Jul	16816976
[Oral anticholinergics in overactive bladder].	2006 Jul	16791627
Gateways to clinical trials.	2006 Jul-Aug	16894408
Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence.	2006 Jun	16686722
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.	2006 Jun	16283422
Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.	2006 Mar	16730617
The emergence of new drugs for overactive bladder.	2006 Mar	16503831
Management of overactive bladder and urge urinary incontinence in the elderly patient.	2006 Mar	16483866
Pharmacologic management of overactive bladder: practical options for the primary care physician.	2006 Mar	16483865
Using anticholinergics to treat overactive bladder: the issue of treatment tolerability.	2006 Mar	16483863
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.	2006 Oct 18	17054185
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.	2006 Sep	16625311
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.	2007 Mar	17341526
An unusual cause of postoperative detrusor overactivity.	2007 Oct	17333438

Patents

Sample Use Guides

In Vivo Use Guide

5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily.

Route of Administration: Oral

In Vitro Use Guide

The inhibitory effect of solifenacin (dose range: 10^-10 - 10^-6 M) for bladder smooth muscle cells (pK(i)=8.12) was 3.6-fold more potent than that for salivary gland cells (pK(i)=7.57).

Name

Type

Language

SOLIFENACIN

Official Name

English

solifenacin [INN]

Common Name

English

NSC-759144

Code

English

SOLIFENACIN [MI]

Common Name

English

Solifenacin [WHO-DD]

Common Name

English

SOLIFENACIN [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

G04CA53